Literature DB >> 20509858

Interstitial lung disease associated to erlotinib treatment: a case report.

Yolanda Del Castillo1, Paulina Espinosa, Fernanda Bodí, Raquel Alcega, Emma Muñoz, Carlos Rabassó, David Castander.   

Abstract

INTRODUCTION: Few cases of pulmonary toxicity related to epidermal growth factor receptor-targeted agents have been described. CASE
PRESENTATION: We report a case of a 63-year-old white male with stage IV non-small cell lung cancer treated with erlotinib who developed a interstitial lung disease.
CONCLUSION: Respiratory symptoms during treatment with erlotinib should alert clinicians to rule out pulmonary toxicity. Early erlotinib withdrawal and corticoid administration were successful.

Entities:  

Year:  2010        PMID： 20509858      PMCID： PMC2834622          DOI： 10.1186/1757-1626-3-59

Source DB:  PubMed          Journal:  Cases J        ISSN： 1757-1626


  8 in total

1.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Authors:  Roy S Herbst; Diane Prager; Robert Hermann; Lou Fehrenbacher; Bruce E Johnson; Alan Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David Ramies; David H Johnson; Vincent A Miller
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

Review 2.  Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee.

Authors:  G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R LeGall; A Morris; R Spragg
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

Review 3.  Clinical implications of the mechanism of epidermal growth factor receptor inhibitors.

Authors:  John Marshall
Journal:  Cancer       Date:  2006-09-15       Impact factor: 6.860

4.  Pulmonary toxicity associated with erlotinib.

Authors:  Vincent Liu; Dorothy A White; Maureen F Zakowski; William Travis; Mark G Kris; Michelle S Ginsberg; Vincent A Miller; Christopher G Azzoli
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

5.  FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.

Authors:  Martin H Cohen; Grant A Williams; Rajeshwari Sridhara; Gang Chen; Richard Pazdur
Journal:  Oncologist       Date:  2003

6.  Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.

Authors:  Demosthenes Makris; Arnaud Scherpereel; Marie Christine Copin; Guillaume Colin; Luc Brun; Jean Jacques Lafitte; Charles Hugo Marquette
Journal:  BMC Cancer       Date:  2007-08-05       Impact factor: 4.430

7.  Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.

Authors:  Paul A Bunn; Nick Thatcher
Journal:  Oncologist       Date:  2008

Review 8.  Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.

Authors:  G Blackledge; S Averbuch
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640
  8 in total
  2 in total

1.  Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Seiichiro Sakao; Koichiro Tatsumi
Journal:  Oncol Lett       Date:  2012-08-21       Impact factor: 2.967

2.  Development of Nanocochleates Containing Erlotinib HCl and Dexketoprofen Trometamol and Evaluation of In Vitro Characteristic Properties.

Authors:  Özlem Çoban; Zelihagül Değim
Journal:  Turk J Pharm Sci       Date:  2018-04-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.